141 related articles for article (PubMed ID: 36422263)
1. The Discovery of Potential SARS-CoV-2 Natural Inhibitors among 4924 African Metabolites Targeting the Papain-like Protease: A Multi-Phase In Silico Approach.
Elkaeed EB; Khalifa MM; Alsfouk BA; Alsfouk AA; El-Attar AMM; Eissa IH; Metwaly AM
Metabolites; 2022 Nov; 12(11):. PubMed ID: 36422263
[TBL] [Abstract][Full Text] [Related]
2. Discovery of Potential SARS-CoV-2 Papain-like Protease Natural Inhibitors Employing a Multi-Phase In Silico Approach.
Elkaeed EB; Metwaly AM; Alesawy MS; Saleh AM; Alsfouk AA; Eissa IH
Life (Basel); 2022 Sep; 12(9):. PubMed ID: 36143445
[TBL] [Abstract][Full Text] [Related]
3. Isolation and In Silico Anti-SARS-CoV-2 Papain-Like Protease Potentialities of Two Rare 2-Phenoxychromone Derivatives from
Suleimen YM; Jose RA; Suleimen RN; Arenz C; Ishmuratova M; Toppet S; Dehaen W; Alsfouk AA; Elkaeed EB; Eissa IH; Metwaly AM
Molecules; 2022 Feb; 27(4):. PubMed ID: 35209006
[TBL] [Abstract][Full Text] [Related]
4. Computer-assisted drug discovery of potential natural inhibitors of the SARS-CoV-2 RNA-dependent RNA polymerase through a multi-phase
Elkaeed EB; Alsfouk BA; Ibrahim TH; Arafa RK; Elkady H; Ibrahim IM; Eissa IH; Metwaly AM
Antivir Ther; 2023 Oct; 28(5):13596535231199838. PubMed ID: 37669909
[TBL] [Abstract][Full Text] [Related]
5. Chemical-informatics approach to COVID-19 drug discovery: Monte Carlo based QSAR, virtual screening and molecular docking study of some
Amin SA; Ghosh K; Gayen S; Jha T
J Biomol Struct Dyn; 2021 Aug; 39(13):4764-4773. PubMed ID: 32568618
[TBL] [Abstract][Full Text] [Related]
6.
Huynh T; Cornell W; Luan B
Front Chem; 2020; 8():624163. PubMed ID: 33614597
[TBL] [Abstract][Full Text] [Related]
7. A novel robust inhibitor of papain-like protease (PLpro) as a COVID-19 drug.
Soleimani Asl S; Roozbahani MH
J Biomol Struct Dyn; 2023 Aug; ():1-8. PubMed ID: 37578047
[TBL] [Abstract][Full Text] [Related]
8. In silico discovery of 3 novel quercetin derivatives against papain-like protease, spike protein, and 3C-like protease of SARS-CoV-2.
Bhattacharya K; Bordoloi R; Chanu NR; Kalita R; Sahariah BJ; Bhattacharjee A
J Genet Eng Biotechnol; 2022 Mar; 20(1):43. PubMed ID: 35262828
[TBL] [Abstract][Full Text] [Related]
9. Discovery of Novel and Highly Potent Inhibitors of SARS CoV-2 Papain-Like Protease Through Structure-Based Pharmacophore Modeling, Virtual Screening, Molecular Docking, Molecular Dynamics Simulations, and Biological Evaluation.
Tian X; Zhao Q; Chen X; Peng Z; Tan X; Wang Q; Chen L; Yang Y
Front Pharmacol; 2022; 13():817715. PubMed ID: 35264955
[No Abstract] [Full Text] [Related]
10. Computational study of the binding orientation and affinity of noncovalent inhibitors of the papain-like protease (PLpro) from SARS-CoV-1 considering the protein flexibility by using molecular dynamics and cross-docking.
Castillo-Campos L; Velázquez-Libera JL; Caballero J
Front Mol Biosci; 2023; 10():1215499. PubMed ID: 37426421
[TBL] [Abstract][Full Text] [Related]
11. Isolation and
Wanas AS; Radwan MM; Marzouk AA; Elkaeed EB; Alsfouk BA; Mostafa AE; Eissa IH; Metwaly AM; ElSohly MA
Nat Prod Res; 2023 Dec; ():1-14. PubMed ID: 38100380
[TBL] [Abstract][Full Text] [Related]
12. Binding of SARS-CoV Covalent Non-Covalent Inhibitors to the SARS-CoV-2 Papain-Like Protease and Ovarian Tumor Domain Deubiquitinases.
Sivakumar D; Stein M
Biomolecules; 2021 May; 11(6):. PubMed ID: 34071582
[TBL] [Abstract][Full Text] [Related]
13. Computational Evidences of Phytochemical Mediated Disruption of PLpro Driven Replication of SARS-CoV-2: A Therapeutic Approach against COVID-19.
Balkrishna A; Mittal R; Arya V
Curr Pharm Biotechnol; 2021; 22(10):1350-1359. PubMed ID: 33176643
[TBL] [Abstract][Full Text] [Related]
14.
Sanachai K; Mahalapbutr P; Sanghiran Lee V; Rungrotmongkol T; Hannongbua S
J Phys Chem B; 2021 Dec; 125(50):13644-13656. PubMed ID: 34904832
[TBL] [Abstract][Full Text] [Related]
15. Modeling of noncovalent inhibitors of the papain-like protease (PLpro) from SARS-CoV-2 considering the protein flexibility by using molecular dynamics and cross-docking.
Valdés-Albuernes JL; Díaz-Pico E; Alfaro S; Caballero J
Front Mol Biosci; 2024; 11():1374364. PubMed ID: 38601323
[TBL] [Abstract][Full Text] [Related]
16. Discovery of Some Antiviral Natural Products to Fight Against Novel Coronavirus (SARS-CoV-2) Using an
Shah A; Patel V; Parmar B
Comb Chem High Throughput Screen; 2021; 24(8):1271-1280. PubMed ID: 32881661
[TBL] [Abstract][Full Text] [Related]
17. Identification of potential plant-based inhibitor against viral proteases of SARS-CoV-2 through molecular docking, MM-PBSA binding energy calculations and molecular dynamics simulation.
Gogoi B; Chowdhury P; Goswami N; Gogoi N; Naiya T; Chetia P; Mahanta S; Chetia D; Tanti B; Borah P; Handique PJ
Mol Divers; 2021 Aug; 25(3):1963-1977. PubMed ID: 33856591
[TBL] [Abstract][Full Text] [Related]
18. Phytocompounds as potential inhibitors of SARS-CoV-2 Mpro and PLpro through computational studies.
Rudrapal M; Celik I; Chinnam S; Azam Ansari M; Khan J; Alghamdi S; Almehmadi M; Zothantluanga JH; Khairnar SJ
Saudi J Biol Sci; 2022 May; 29(5):3456-3465. PubMed ID: 35233172
[TBL] [Abstract][Full Text] [Related]
19. Discovery of genistein derivatives as potential SARS-CoV-2 main protease inhibitors by virtual screening, molecular dynamics simulations and ADMET analysis.
Liu J; Zhang L; Gao J; Zhang B; Liu X; Yang N; Liu X; Liu X; Cheng Y
Front Pharmacol; 2022; 13():961154. PubMed ID: 36091808
[No Abstract] [Full Text] [Related]
20. Structure-based drug designing of naphthalene based SARS-CoV PLpro inhibitors for the treatment of COVID-19.
Bhati S
Heliyon; 2020 Nov; 6(11):e05558. PubMed ID: 33251371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
